[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Maze Therapeutics Inc (MAZE)

Maze Therapeutics Inc (MAZE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Will Maze Therapeutics Finally Explain What Justifies Burning Through That Much Cash?

Maze Therapeutics Inc (MAZE) is scheduled to report first-quarter 2026 earnings on May 13, 2026, with analysts expecting a loss of $0.43 per share. The clinical-stage biotechnology company faces a critical test as investors assess progress on its lead APOL1 inhibitor program following the dramatic 35% post-earnings selloff in March, despite what management characterized as "positive" Phase 2 trial data. With the stock trading 25% below its 50-day moving average and technical indicators flashing sell signals, the upcoming report will determine whether MAZE can stabilize investor confidence or faces further pressure from its substantial cash burn and pre-revenue status.

Fundamentals

See More
  • Market Capitalization, $K 1,282,787
  • Shares Outstanding, K 49,759
  • Annual Sales, $ 0 K
  • Annual Income, $ -131,120 K
  • EBIT $ -143 M
  • EBITDA $ -141 M
  • 60-Month Beta 2.50
  • Price/Sales 66.45
  • Price/Cash Flow N/A
  • Price/Book 3.46

Options Overview Details

View History
  • Implied Volatility 87.19% (+1.36%)
  • Historical Volatility 40.79%
  • IV Percentile 39%
  • IV Rank 10.66%
  • IV High 228.70% on 03/10/26
  • IV Low 70.30% on 04/29/26
  • Expected Move (DTE 1) 1.02 (3.78%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 1,806
  • Volume Avg (30-Day) 184
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 2,791
  • Open Int (30-Day) 3,295
  • Expected Range 25.94 to 27.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.71
  • Number of Estimates 6
  • High Estimate $-0.57
  • Low Estimate $-0.78
  • Prior Year $-0.77
  • Growth Rate Est. (year over year) +7.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.80 +8.71%
on 05/07/26
29.08 -7.31%
on 04/22/26
-0.46 (-1.68%)
since 04/13/26
3-Month
24.80 +8.71%
on 05/07/26
53.65 -49.75%
on 03/16/26
-19.05 (-41.40%)
since 02/13/26
52-Week
8.24 +226.99%
on 05/15/25
53.65 -49.75%
on 03/16/26
+17.10 (+173.43%)
since 05/13/25

Most Recent Stories

More News
Will Maze Therapeutics Finally Explain What Justifies Burning Through That Much Cash?

Barchart Research What to Expect from MAZE Earnings MAZE Generated May 12, 2026 Current Price $25.78 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 10.21% Will Maze Therapeutics Finally...

MAZE : 26.96 (+4.58%)
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026...

MAZE : 26.96 (+4.58%)
Maze Therapeutics Announces $150 Million Registered Offering

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common...

MAZE : 26.96 (+4.58%)
U.S. Jobs Figures Issued in Short Week

MondayFeatured Earnings Maze Therpautics (NASDAQ:MAZE) (Q4) EPS for loss of 73 cents, compared ...

AYI : 283.85 (-1.49%)
MKC : 45.60 (-2.63%)
FDS : 201.87 (-6.51%)
MSM : 106.76 (-0.15%)
CAG : 14.09 (+0.64%)
NKE : 42.34 (-0.02%)
PRGS : 26.37 (-2.94%)
POET : 14.37 (+4.66%)
LW : 41.54 (+0.31%)
ANGO : 10.84 (-0.55%)
MAZE : 26.96 (+4.58%)
LNN : 105.50 (-2.38%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 26.96 (+4.58%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 26.96 (+4.58%)
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease

– At week 12, treatment with MZE829 resulted in a 35.6% mean uACR reduction in broad AMKD patients, 50% of the patients achieved a greater than 30% reduction in uACR, and treatment was well-tolerated...

MAZE : 26.96 (+4.58%)
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference...

MAZE : 26.96 (+4.58%)
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 26.96 (+4.58%)
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients...

MAZE : 26.96 (+4.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases. Maze Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif....

See More

Key Turning Points

3rd Resistance Point 29.30
2nd Resistance Point 28.18
1st Resistance Point 27.57
Last Price 26.96
1st Support Level 25.84
2nd Support Level 24.72
3rd Support Level 24.11

See More

52-Week High 53.65
Fibonacci 61.8% 36.31
Fibonacci 50% 30.95
Last Price 26.96
Fibonacci 38.2% 25.59
52-Week Low 8.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.